Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Lipidology

• Publication date

  2010-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/clp.10.4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular Health and Aromatase Inhibitors

  2012cited by this paper
• Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

  2009cited by this paper
• Hormone replacement therapy and cardiovascular disease revisited

  2009cited by this paper
• Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.

  2009cited by this paper
• Effects of hormonal treatment on lipids in patients with cancer.

  2009cited by this paper
• Safety of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer

  2008cited by this paper
• Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective

  2007cited by this paper
• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  2007cited by this paper
• Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

  2007cited by this paper
• The current status of breast cancer chemoprevention: A star is born

  2007cited by this paper
• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

  2007cited by this paper
• Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

  2007cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Conjugated equine estrogens and coronary heart disease : The women's health initiative

  2006cited by this paper
• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  2006cited by this paper
• Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

  2006cited by this paper
• Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment

  2006cited by this paper
• Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

  2005cited by this paper
• 6th annual san antonio breast cancer symposium

  2005cited by this paper
• Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

  2005cited by this paper
• The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study

  2005cited by this paper
• The effects of aromatase inhibitors on lipids and thrombosis

  2005cited by this paper
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

  2005cited by this paper
• Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)

  2005cited by this paper
• The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

  2005cited by this paper
• Aromatase inhibitors for therapy of advanced breast cancer.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy

  2005cited by this paper
• Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer

  2005cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• Effects of conjugated equine estrogen in postmenopausal women with hysterectomy

  2004cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients — a preliminary study

  2004cited by this paper
• Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

  2004cited by this paper
• Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Risk of ischemic stroke with tamoxifen treatment for breast cancer

  2004cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Estrogen plus progestin and the risk of coronary heart disease.

  2003cited by this paper
• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

  2003cited by this paper
• Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).

  2003cited by this paper
• Long-Term Mortality of Women with a Diagnosis of Breast Cancer

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• Aromatase Inhibitors and Inactivators for Breast Cancer Therapy

  2002cited by this paper
• Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-inflammatory Effect

  2001cited by this paper
• Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus.

  2001cited by this paper
• Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.

  2001cited by this paper
• Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.

  2000cited by this paper
• The role of small, dense low density lipoprotein (LDL): a new look.

  2000cited by this paper
• Risks versus benefits in the clinical application of aromatase inhibitors.

  1999cited by this paper
• Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.

  1999cited by this paper
• The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group.

  1999cited by this paper
• Coronary heart disease risk factors and menopause: a study in 1684 French women.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

  1999cited by this paper
• Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.

  1998cited by this paper
• Biologic activity of tamoxifen at low doses in healthy women.

  1998cited by this paper
• Effect of tamoxifen on serum lipid metabolism.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer.

  1997cited by this paper
• The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property.

  1996cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women.

  1996cited by this paper
• Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

  1995cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.

  1994cited by this paper
• Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer

  1994cited by this paper
• Plasma lipoprotein levels as predictors of cardiovascular death in women.

  1993cited by this paper
• Influence of age and menopause on serum lipids and lipoproteins in healthy women.

  1993cited by this paper
• Report of the Conference on Low Blood Cholesterol: Mortality Associations

  1992cited by this paper
• HRT: an analysis of benefits, risks and costs.

  1992cited by this paper
• Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

  1992cited by this paper
• Exemestane (FCE 24304), a new steroidal aromatase inhibitor.

  1992cited by this paper
• Dietary lipids and the low blood cholesterol-cancer association.

  1992cited by this paper
• Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

  1992cited by this paper
• Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆

  1991cited by this paper
• 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.

  1988cited by this paper
• Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

  1988cited by this paper
• Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study.

  1988cited by this paper

• Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice

  2026cites this paper
• Lifestyle factors and cardiometabolic risk in breast cancer patients under different hormones therapy

  2025cites this paper
• Breast Cancer Survivors Undergoing Endocrine Therapy Have a Worrying Risk Factor Profile for Cardiovascular Diseases

  2021cites this paper
• Cardiovascular toxicity of breast cancer treatment: an update

  2021cites this paper
• Breast Cancer Survivors Undergoing Endocrine Therapy Have a Worrying Risk Factor Profile for Cardiovascular Diseases

  2021cites this paper
• Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study

  2020cites this paper
• Tamoxifen Effects on the lipid profile in premenopausal women with Breast cancer: A follow up study

  2018cites this paper